BioInvent International
40.65 SEK -2.28%1 investor is following this company
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BINV
Daily low / high price
40.2 / 42.2
SEK
Market cap
2.67B SEK
Turnover
3.56M SEK
Volume
87K
Latest videos
Financial calendar
Interim report
29.08.2024
Interim report
31.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Redmile Group, LLC | 15.2 % | 15.2 % |
Van Herk Investments | 10.1 % | 10.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioInvent International AB: BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment
BioInvent announces new clinical trial collaboration and supply agreement with MSD to evaluate BI-1607 in combination with KEYTRUDA (pembrolizumab) and ipilimumab
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools